Vor Bio and RemeGen Seal $4B Global License Agreement
Vor Bio, RemeGen sign Global License Agreement for RC98 development.
Vor Bio, RemeGen sign Global License Agreement for RC98 development.
Novartis makes a $750M flagship pact to address cardiovascular disease innovation.
South Korea’s new pharma pricing reforms reward innovation and expand access for industry.
FDA investigates Elevidys deaths, raising new safety and regulatory questions for gene therapies.
Gilead and Kymera seal a $750M deal for innovative CDK2 molecular glue degraders in oncology.
Neuron23 advances NEU-411 into Phase II Parkinson’s trial, driven by biomarker-based strategies and strong investor support.
Quick Summary: NICE has published new interventional procedures guidance recommending the use of transcatheter aortic valve implantation (TAVI) for patients with native aortic valve regurgitation. This guidance enables wider access to TAVI as a less invasive alternative to open-heart surgery for eligible NHS patients, with a key focus on multidisciplinary team-based patient selection and … Read more
NICE empowers NHS with digital health tech for children’s mental health, boosting access and efficiency.
GSK’s Benlysta autoinjector gains FDA nod for pediatric lupus nephritis, enabling at-home treatment.
SINTX acquires SiNAPTIC assets, targeting the $1.3B foot and ankle fusion implant market.